During the past decade, New England Retina Consultants conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 2 clinical trials were completed, i.e. on average, 15.4% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 1 clinical trials were completed. i.e. 11.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New England Retina Consultants" #1 sponsor was "Apellis Pharmaceuticals, Inc." with 3 trials, followed by "Kodiak Sciences Inc" with 3 trials sponsored, "Aldeyra Therapeutics, Inc." with 1 trials sponsored, "Clearside Biomedical, Inc." with 1 trials sponsored and "Curacle Co., Ltd." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New England Retina Consultants" #1 collaborator was "Bayer" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Juvenile Diabetes Research Foundation" with 1 trials as a collaborator and "Laboratorios Thea, France" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "New England Retina Consultants" are "Diabetic Macular Edema" (3 trials), "Geographic Atrophy" (2 trials), "Age-Related Macular Degeneration" (1 trials), "Age-related Macular Degeneration" (1 trials) and "Geographic Atrophy Secondary to Age-related Macular Degeneration" (1 trials). Many other conditions were trialed in "New England Retina Consultants" in a lesser frequency.

Most popular intervention types in "New England Retina Consultants" are "Drug" (10 trials), "Other" (7 trials), "Combination Product" (2 trials), "Procedure" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (5 trials), "Aflibercept" (3 trials), "KSI-301" (3 trials), "APL-2" (2 trials) and "ADX-2191 (intravitreal methotrexate 0.8%)" (1 trials). Other intervention names were less common.

The vast majority of trials in "New England Retina Consultants" are 15 trials for "All" genders.

Currently, there are NaN active trials in "New England Retina Consultants". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in New England Retina Consultants, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in New England Retina Consultants, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".